Biodesix Inc. (BDSX)
Nasdaq · Services-Medical Laboratories · Services · CIK 1439725 · fiscal year ends in Dec
Closing price $23.26 on 30 Oct 2026; 52-week range $5.46 to $30.60.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $102.9M
- Revenue growth
- 34.5%
- Net income, last twelve months
- -$27.8M
- Earnings per share
- -$3.17
- Operating margin
- -20.0%
- Net margin
- -27.0%
- Free cash flow
- -$20.2M
- Return on equity
- -303.6%
- Market value
- $245.4M
- Cash
- $30.0M
- Debt
- $50.0M
- Debt to equity
- 5.47
- Shares outstanding
- 10.5M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $88.5M | -$27.9M | -$35.3M | -$4.67 | -$23.5M | 10-K filed 26 Feb 2026 |
| FY2024 | 31 Dec 2024 | $71.3M | -$34.5M | -$42.9M | -$6.60 | -$51.9M | 10-K filed 3 Mar 2025 |
| FY2023 | 31 Dec 2023 | $49.1M | -$41.3M | -$52.1M | -$12.80 | -$45.8M | 10-K filed 1 Mar 2024 |
| FY2022 | 31 Dec 2022 | $38.2M | -$50.6M | -$65.4M | -$31.00 | -$48.3M | 10-K filed 6 Mar 2023 |
| FY2021 | 31 Dec 2021 | $54.5M | -$40.9M | -$43.2M | -$31.60 | -$30.5M | 10-K filed 14 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $26.9M | -$7.3M | -$0.71 |
| Q1 FY2026 | 31 Mar 2026 | $25.6M | -$7.8M | -$0.81 |
| Q4 FY2025 | 31 Dec 2025 | $28.8M | -$4.0M | -$0.49 |
| Q3 FY2025 | 30 Sep 2025 | $21.8M | -$8.7M | -$1.16 |
| Q2 FY2025 | 30 Jun 2025 | $20.0M | -$11.5M | -$1.60 |
| Q1 FY2025 | 31 Mar 2025 | $18.0M | -$11.1M | -$1.60 |
| Q4 FY2024 | 31 Dec 2024 | $20.4M | -$8.3M | -$1.20 |
| Q3 FY2024 | 30 Sep 2024 | $18.2M | -$10.3M | -$1.40 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Diagnostic Tests | $79.2M | 89.5% |
| Development Services | $9.3M | 10.5% |
Company events
The newest 8-K filings of 55 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 5 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 20 May 2026 | 8-K | Shareholder vote | 5.07, 9.01 |
| 4 May 2026 | 8-K | Results | 2.02, 9.01 |
| 26 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Jan 2026 | 8-K/A | Results | 2.02, 9.01 |
| 3 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 1 Oct 2025 | 8-K | Other events | 8.01 |
| 15 Sep 2025 | 8-K | Shareholder rights change, Bylaws or fiscal year change | 3.03, 5.03, 9.01 |
| 11 Sep 2025 | 8-K | Other events | 8.01, 9.01 |
| 7 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 21 May 2025 | 8-K | Shareholder vote | 5.07, 9.01 |
| 13 May 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 188 held.
| Filed | Form | Period |
|---|---|---|
| 5 Aug 2026 | 10-Q | 30 Jun 2026 |
| 5 Aug 2026 | 8-K | 5 Aug 2026 |
| 29 May 2026 | EFFECT | – |
| 27 May 2026 | CORRESP | – |
| 26 May 2026 | UPLOAD | – |
| 21 May 2026 | S-3 | – |
| 20 May 2026 | 8-K | 19 May 2026 |
| 4 May 2026 | 10-Q | 31 Mar 2026 |
| 4 May 2026 | 8-K | 4 May 2026 |
| 9 Apr 2026 | ARS | 31 Dec 2025 |
| 9 Apr 2026 | DEFA14A | – |
| 9 Apr 2026 | DEF 14A | 19 May 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 12 Aug 2026 | Schuler Jack W, 10% owner | Purchase | 15,000 | $24.47 | $367.0K | 555,810 | 13 Aug 2026 |
| 11 Aug 2026 | Schuler Jack W, 10% owner | Purchase | 13,700 | $24.01 | $328.9K | 540,810 | 12 Aug 2026 |
| 10 Aug 2026 | Schuler Jack W, 10% owner | Purchase | 13,900 | $24.25 | $337.0K | 527,110 | 12 Aug 2026 |
| 23 Feb 2026 | Pestano Gary Anthony, Chief Development Officer | Sale outside a trading plan | 556 | $12.78 | $7.1K | 10,359 | 23 Feb 2026 |
| 23 Feb 2026 | O'Kane Kieran, Chief Commercial Officer | Sale outside a trading plan | 535 | $12.78 | $6.8K | 9,819 | 23 Feb 2026 |
| 23 Feb 2026 | Cowie Robin Harper, CFO, Sec'y & Treasurer | Sale outside a trading plan | 535 | $12.78 | $6.8K | 16,231 | 23 Feb 2026 |
| 23 Feb 2026 | Vazquez Chris, Chief Accounting Officer | Sale outside a trading plan | 211 | $12.78 | $2.7K | 1,586 | 23 Feb 2026 |
| 23 Feb 2026 | Hutton Scott, President & CEO | Sale outside a trading plan | 1,490 | $12.78 | $19.0K | 48,767 | 23 Feb 2026 |
| 10 Feb 2026 | O'Kane Kieran, Chief Commercial Officer | Sale outside a trading plan | 584 | $10.08 | $5.9K | 8,885 | 11 Feb 2026 |
| 10 Feb 2026 | Vazquez Chris, Chief Accounting Officer | Sale outside a trading plan | 101 | $10.08 | $1.0K | 1,234 | 11 Feb 2026 |
| 10 Feb 2026 | Hutton Scott, President & CEO | Sale outside a trading plan | 3,559 | $10.08 | $35.9K | 45,413 | 11 Feb 2026 |
| 10 Feb 2026 | Cowie Robin Harper, CFO, Sec'y & Treasurer | Sale outside a trading plan | 941 | $10.08 | $9.5K | 15,297 | 11 Feb 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 23 Feb 2026 | Hutton Scott, Officer, Director | 1,490 | $19.0K | 23 Feb 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 18 Jun 2026 | Soleus Capital Master Fund, L.P. | 13G | 5.1% | 525.2K |
| 15 May 2026 | Perceptive Advisors LLC | 13G amended | 4.6% | 483.7K |
| 8 May 2026 | Soleus Capital Master Fund, L.P. | 13G amended | 4.1% | 416.6K |
| 28 Apr 2026 | Orin Hirschman | 13G | 7.7% | 758.3K |
| 27 Jan 2026 | SCHULER JACK W | 13D amended | 24% | 2.3M |
| 26 Jan 2026 | Telemark Asset Management, LLC | 13G | 5.4% | 427.8K |
| 23 Jan 2026 | Telemark Asset Management, LLC | 13G amended | 4.1% | 327.8K |
| 13 Jan 2026 | Soleus Capital Master Fund, L.P. | 13G | 6.3% | 500.0K |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 209.5K | +3.79% | 2.35 |
| 30 Sep 2026 | 201.8K | -5.68% | 1.84 |
| 15 Sep 2026 | 214.0K | -2.89% | 3.29 |
| 31 Aug 2026 | 220.4K | +46.84% | 1.33 |
| 14 Aug 2026 | 150.1K | -4.52% | 1.58 |
| 31 Jul 2026 | 157.2K | -6.42% | 2.68 |
| 15 Jul 2026 | 168.0K | +59.32% | 2.19 |
| 30 Jun 2026 | 105.4K | +0.73% | 1 |
Funds that hold it
From each fund's latest Form 13F.
49 funds held it at 30 Jun 2026: 25 added and 13 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| AIGH Capital Management LLC | 678,328 | $15.3M | -80,000 |
| Soleus Capital Management, L.P. | 585,958 | $13.2M | +169,359 |
| Telemark Asset Management, LLC | 489,824 | $11.0M | 0 |
| Aberdeen Group plc | 388,639 | $8.8M | -69,799 |
| Vanguard Capital Management LLC | 284,169 | $6.4M | +29,008 |
| Essex Investment Management Co. LLC | 241,915 | $5.5M | +109,829 |
| Opaleye Management Inc. | 180,000 | $4.1M | -58,047 |
| Marshall Wace, LLP | 116,199 | $2.6M | -25,437 |
| Perceptive Advisors LLC | 108,694 | $2.5M | +108,694 |
| Jane Street Group, LLC | 91,506 | $2.1M | +64,475 |
Peers
Companies in the same industry.
- Natera, Inc. (NTRA): revenue $2.7B, market value $59.5B
- Labcorp Holdings Inc. (LH): revenue $14.6B, market value $29.4B
- Quest Diagnostics Inc. (DGX): revenue $11.8B, market value $27.7B
- Guardant Health, Inc. (GH): revenue $1.2B, market value $23.9B
- Caris Life Sciences, Inc. (CAI): revenue $989.6M, market value $9.7B
- Grail, Inc. (GRAL): revenue $165.3M, market value $6.4B
- RadNet, Inc. (RDNT): revenue $2.3B, market value $5.8B
- BillionToOne, Inc. (BLLN): revenue $397.4M, market value $5.3B
- CareDx, Inc. (CDNA): revenue $497.4M, market value $4.6B
- Veracyte, Inc. (VCYT): revenue $561.9M, market value $4.0B